Dramatic resolution of cutaneous lymphoid hyperplasia after receiving intravenous immunoglobulin for COVID-19.

Balighi, Kamran; Ansari, Mahshid Sadat; Hashemi Urimi, Behnam; Ghanadan, Alireza; Tootoonchi, Nasim

Balighi, Kamran; Ansari, Mahshid Sadat; Hashemi Urimi, Behnam; Ghanadan, Alireza; Tootoonchi, Nasim.

Balighi K; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ansari MS; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hashemi Urimi B; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ghanadan A; Department of Dermatopathology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Tootoonchi N; Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Dermatol Ther ; 35(4): e15347, 2022 04.

Article in English | MEDLINE | ID: covidwho-1662257

Subject(s)

COVID-19; Pseudolymphoma; Skin Neoplasms; Humans; Hyperplasia; Immunoglobulins, Intravenous/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Pseudolymphoma / COVID-19 Limits: Humans Language: English Journal: Dermatol Ther Journal subject: Dermatology Year: 2022 Document Type: Article Affiliation country: Dth.15347

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google